The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is revolutionary as it is the first clinically approved ISH test to accurately assess B-cell lymphoma subtypes.
With the ability to distinguish B-cell cancers from normal immune responses, this test provides crucial diagnostic clarity, aiding healthcare providers in delivering appropriate treatments.
Around 85 percent of non-Hodgkin lymphoma cases are B-cell lymphoma, underscoring the significant impact of the VENTANA assay in improving patient outcomes.
After receiving FDA 510(k) clearance, Roche's VENTANA assay promises to enhance diagnosis and treatment access for patients suffering from B-cell malignancies globally.
Collection
[
|
...
]